An umbrella review of 27 studies involving 2,156 older adults found that animal-assisted interventions (AAIs) reduced depressive symptoms with a standardized effect size of 0.73, which crosses the threshold for clinical meaningfulness. Trial sequential analysis confirmed sufficient evidence exists to support this conclusion.
Depression affects up to 30% of older adults and carries serious health consequences, including increased morbidity and mortality. Yet treatment options remain limited by medication side effects, cost, and access barriers in geriatric populations. Researchers conducted a comprehensive umbrella review—a systematic evaluation of existing systematic reviews and meta-analyses—to synthesize fragmented evidence on whether animal-assisted interventions could serve as an evidence-supported complement to conventional depression treatment.
The analysis pulled data from five existing systematic reviews that collectively examined 27 unique primary studies across 2,156 older adult participants. The pooled analysis found a standardized mean difference (SMD) of 0.73 in depressive symptom reduction, with a 95% confidence interval of 0.57 to 0.89 (p < 0.001). This effect size exceeds the threshold generally considered clinically meaningful in mental health research. Moderate heterogeneity was observed across studies (I² = 43.4%), which is typical when combining data from interventions that vary in design, duration, and animal types.
The researchers applied trial sequential analysis, a method that determines whether existing evidence is sufficient or if additional studies are needed. The cumulative evidence curve crossed predefined monitoring boundaries at 75% of the required information size, indicating that the current evidence base is robust enough to support conclusions about AAI effectiveness. This finding is important because it suggests researchers have gathered adequate data to confidently recommend AAIs without waiting for substantially more trials.
Overlap between the five systematic reviews was moderate (Corrected Covered Area: 20.4%), meaning the reviews examined somewhat different subsets of primary studies. The authors accounted for this by reanalyzing primary study data to avoid double-counting participants, strengthening the validity of their pooled estimates. The quality of included reviews was assessed using AMSTAR-2, ensuring methodological rigor at the review level.
If you are an older adult experiencing depression, or caring for an older adult with depression, AAIs represent a low-risk option worth discussing with your healthcare provider. The evidence supports pet-interaction as a practical, scalable complement to medication or psychotherapy, not a replacement. Engagement with animals appears to produce measurable mood improvements that align with clinical thresholds used to judge treatment success.
The magnitude of benefit (SMD = 0.73) falls into a range that clinicians consider clinically relevant. To put this in perspective, this is comparable to the effect sizes seen in some antidepressant trials in older populations. Importantly, AAIs carry minimal adverse effects compared to pharmacological interventions, making them particularly suitable for older adults with multiple medications or medical comorbidities.
The type of animal, duration of intervention, and format (individual vs. group, facility-based vs. home-based) likely vary across the 27 studies, suggesting that different AAI approaches may work. If direct pet ownership is not feasible, alternatives like structured visitation programs, group pet therapy sessions, or even brief interactions with therapy animals in clinical settings appear supported by evidence.
The evidence is not a claim that AAIs will work for everyone or that they eliminate the need for other treatments. Rather, it indicates that on average, older adults with depression show measurable symptom reduction following animal-assisted interventions. Individual response will vary, and AAIs work best as part of a comprehensive care approach.
| Parameter | Detail |
|---|---|
| Study Type | Umbrella review and meta-analysis with trial sequential analysis |
| Total Participants | 2,156 older adults across 27 unique primary studies |
| Included Reviews | 5 systematic reviews and meta-analyses |
| Primary Outcome | Standardized mean difference in depressive symptom scores |
| Effect Size | SMD = 0.73 (95% CI: 0.57-0.89, p < 0.001) |
| Heterogeneity | I² = 43.4% (moderate) |
| TSA Result | Evidence curve crossed monitoring boundaries at 75% information size |
| Review Overlap | Corrected Covered Area = 20.4% (moderate) |
| Quality Assessment | AMSTAR-2 |
| Journal | Aging Clinical and Experimental Research |
| PubMed ID | 42400739 |
| PROSPERO Registration | CRD420251250448 |
Umbrella review examining animal-assisted interventions for depression in older adults:
https://pubmed.ncbi.nlm.nih.gov/42400739/
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.